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Bruno Crestani1,2,3,4,6*, Valerie Besnard1,4, Laurent Plantier1,2,4,5, Keren Borensztajn1,4 and Arnaud Mailleux1,4Fibrotic lung disorders, either idiopathic, or associated
with a specific etiology or a specific condition such as
scleroderma, are increasingly recognized. As a whole
they constitute a group of diseases characterized by the
progressive destruction of the lung which ultimately
leads to chronic respiratory failure and death. Improving
the prognosis of these disorders requires the identifica-
tion of drugs capable of inhibiting partially or totally the
progression of lung fibrosis, and perhaps of reversing
established fibrosis. This has been the focus of huge ef-
forts from academic groups and pharma companies, and
more than 20 different molecules are being investigated
in clinical trials in idiopathic pulmonary fibrosis (IPF) a
well defined and relatively frequent fibrotic lung disease
of unknown etiology. However, until now, only one drug
has been approved for lung fibrosis treatment. This
drug, pirfenidone, has been shown to slow the decline of
lung function in IPF, but no drug has demonstrated ef-
fects on survival in patients with lung fibrosis [1]. The
effort must be prolonged and intensified.
Beside IPF, scleroderma-associated lung fibrosis is a
well recognized fibrotic disorder. With pulmonary
hypertension, lung fibrosis is now the main cause of
death of patients with scleroderma [2]. The nature and
pathophysiology of lung fibrosis in IPF and scleroderma
are different. For instance, scleroderma affects mainly
women, whereas IPF predominates in men; usual inter-
stitial pneumonia is the pathological pattern of IPF,
whereas non specific interstitial pneumonia is the main
pattern in patients with scleroderma; the MUC5B pro-
motor polymorphism is associated with IPF whereas it is
not observed in patients with IPF [3]; IPF is rapidly pro-
gressive disorder as compared with the slowly moving
scleroderma-associated lung fibrosis [2].
Fibrotic lung diseases are characterized by the patho-
logical accumulation of fibroblasts, which are thought to* Correspondence: bruno.crestani@bch.aphp.fr
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reproduction in any medium, provided the orbe the main source of the extracellular matrix proteins
which are accumulating in the fibrotic areas. The origin
of fibroblasts is a matter of discussion, and the respect-
ive role of 1) circulating precursors, of 2) epithelial,
mesothelial or endothelial to mesenchymal transition,
and the role of 3) local mesenchymal precursors has
been suggested [4,5]. However, it has been shown that fi-
broblasts isolated from fibrotic lung have abnormal
properties as compared with fibroblasts isolated from
normal lung. For instance, fibroblasts have an increased
capacity to produce extracellular matrix proteins such as
collagen or fibronectin, a relative resistance to apoptosis,
an increased capacity to secrete reactive oxygen species,
and a reduced capacity to secrete anti-fibrotic molecules
such as prostaglandin E2, fibroblast growth factor 7 or
hepatocyte growth factor [5-7]. These profibrotic proper-
ties are maintained in vitro and have been linked at least
in part to epigenetic changes such as increased DNA
methylation or deacetylation, or abnormal micro-RNA
network [8,9]. Targeting lung fibroblasts to treat lung fi-
brotic disorders might be a clue to the future. Therefore,
evaluating lung fibroblasts to identify new fibrotic path-
ways carries important perspectives. In that way, Gisela
Lindhal and colleagues recently compared the mRNA
microarray profile of lung fibroblasts isolated from pa-
tients with IPF, systemic sclerosis, or controls [10]. They
discovered the suppression of a group of interferon-
stimulated genes, which was observed both in sclero-
derma fibroblasts and IPF fibroblasts. This observation,
if confirmed by other groups, is very interesting, as it
identifies a pathway that could be pharmacologically
modulated. Many obstacles however do exist before this
can reach the clinic. First, on the basis of blood and skin
studies, scleroderma is currently considered to be an
interferon-driven disease [11]. Why this could be differ-
ent in lung fibroblasts from scleroderma-associated
interstitial lung disease is difficult to understand now
and will require specific studies. Second, sub-cutaneous
interferon-gamma has been evaluated in the past in a
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a trend toward an improvement of skin sclerosis scores
[12]. We also know from recent trials that systemic ad-
ministration of interferon-beta [13] or interferon-gamma
[14] does not influence the decline of lung function in pa-
tients with IPF. However some groups have suggested giv-
ing interferon through inhalation in order to increase the
concentration in the lung and to somewhat reduce the sys-
temic availability of the molecule [15]. Ten patients with
IPF were prospectively treated with inhaled interferon-
gamma for 80 weeks. The drug appeared to be safe [15].
Whether inhaled interferon-gamma could be useful in the
long term in patients with IPF or scleroderma-associated
interstitial lung disease deserves a rigorously evaluation in
specific trials.
The results of Lindahl and colleagues point to an un-
expected similarity of the microarray of IPF and sclero-
derma lung fibroblasts [10]. Although interesting, these
results need to be confirmed as the number of IPF sam-
ples studied was small. However, such a similarity sug-
gest that a drug targeting lung fibroblasts might work
both in IPF and in scleroderma-associated lung fibrosis,
and perhaps also in other fibrotic disorders.
Further studies are clearly needed, but this study illus-
trates the potential of modern screening methods to
identify unexpected pathways in diseases [16].
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